Magnus Financial Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Magnus Financial Group’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-19,140	Closed	-$73K	–	795
2020 Q1	$73K	Hold	19,140	–	–	0.01%	538
2019 Q4	$97K	Hold	19,140	–	–	0.01%	568
2019 Q3	$97K	Hold	19,140	–	–	0.02%	507
2019 Q2	$118K	Hold	19,140	–	–	0.02%	499
2019 Q1	$89K	Buy	19,140 +977	+5%	+$4.42K	0.02%	495
2018 Q4	$76K	Buy	+18,163	New	+$92.5K	0.02%	414

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Magnus Financial Group's PGNX Position: Q2 2020 in Review

Magnus Financial Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 19,140 shares — an estimated $73K sold.

Magnus Financial Group first reported a position in PGNX in Q4 2018 and held it in 6 quarters. The position peaked at $118K in Q2 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Magnus Financial Group reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Magnus Financial Group sold 19,140 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $73K.
Magnus Financial Group first reported a position in Progenics Pharmaceuticals Inc in Q4 2018 and held it in 6 quarters.
Magnus Financial Group's Progenics Pharmaceuticals Inc position peaked at $118K in Q2 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Magnus Financial Group's 13F filing for Q2 2020, filed 11 Aug 2020.